About AyuGen
AyuGen is a Healthcare company based in Pune (India) founded in 2005 by Krishnan Nandabalan and Manish Pungliya. It offers specialized genomic tests and services for health diagnostics and treatment guidance. It operates on a D2C and B2B model. Its Indian entity Ayugen Biosciences Private Limited reported revenue of ₹1.53 Cr. AyuGen offers products and services including Cervival™ Kit, Amnisure ROM Test, FSH Polymorphism Test, Cardiovascular Risk Test, and Ayuscreen BRCA Test. Its focus areas include Biotechnology, Genomics, Diagnostic Testing and Pharmacogenomics.
Company details
AyuGen Biosciences, founded in 2005, specializes in genomic tests and services to identify disease causes and enable personalized treatments. Based in Pune, India, the company bridges traditional and genomic-based medicine by offering diagnostic kits like Cervival for cervical cancer screening and tests for genetic risks. They serve healthcare professionals and individuals through accurate, preventive diagnostics, focusing on areas such as pharmacogenomics and hereditary risk assessments.
- Headquarters Pune, India
- Founders Krishnan Nandabalan, Manish Pungliya
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ayugen.com
- Social LinkedIn Facebook Instagram
- Legal Name Ayugen Biosciences Private Limited
- Date of Incorporation 20 Jun, 2005
- Jurisdiction Nagar, Pune - 411 005, Maharashtra, India
- Annual Revenue₹1.53 Cr
FY 2025 · +58% YoY
- Net Profit₹15.1 Lakh
FY 2025 · 10% margin
- EBITDA₹21.2 Lakh
FY 2025 · 14% margin
Associated legal entities of AyuGen
AyuGen operates through Ayugen Biosciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ayugen Biosciences Private Limited CIN U85199PN2005PTC020901 | Active | 20 Jun 2005 | Pune, Maharashtra | ₹1.5 Cr | 2 | View details |
Products & Services of AyuGen
AyuGen offers a comprehensive portfolio of products and services, including Cervival™ Kit, Amnisure ROM Test, FSH Polymorphism Test, Cardiovascular Risk Test, and Ayuscreen BRCA Test.
Kit for cervical cancer prevention and screening tests.
Test for accurate diagnosis of fetal membrane rupture.
Test for personalized IVF treatment based on genetics.
Test to evaluate genetic risks for heart diseases.
Test for breast cancer risk assessment through genetics.
Board of directors of Ayugen Biosciences Private Limited (AyuGen)
Ayugen Biosciences Private Limited is the primary company behind AyuGen. The board of Ayugen Biosciences Private Limited currently have 2 directors; the longest-serving is Manish Sampat Pungliya, appointed in 2005. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manish Sampat Pungliya DIN 00383978 | Director | 20 Jun 2005 | 21 yrs 4 mo | Ayugen Biosciences Private Limited |
| Sampat Nensukh Pungliya DIN 00384075 | Director | 20 Jul 2006 | 20 yrs 3 mo | Ayugen Biosciences Private Limited |
People of AyuGen
2 people are tracked at AyuGen (2 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder, Director | Leadership | |
| Founder, Director | Leadership |
Complete people profiles for AyuGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of AyuGen
Figures of Ayugen Biosciences Private Limited, the primary company behind AyuGen, for FY 2025. Revenue was ₹1.53 Cr (+58% year on year). Net profit was ₹15.1 Lakh (10% margin). EBITDA was ₹21.2 Lakh (14% margin). Revenue has grown at a compounded annual rate of -10% over three years and +7% over five years.
- ₹1.53 CrRevenue · FY 2025 · +58% YoY
- ₹15.1 LakhNet profit · 10% margin
- ₹21.2 LakhEBITDA · 14% margin
- ₹11.7 LakhPaid-up capital
- -10%Revenue CAGR, 3 years
- +7%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Ayugen Biosciences Private Limited are on its company page.
Detailed financial statements for AyuGen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AyuGen
AyuGen was founded in 2005.
AyuGen is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
The primary company behind AyuGen, Ayugen Biosciences Private Limited, reported revenue of ₹1.53 Cr for FY 2025, up 58% year on year.
AyuGen Biosciences, founded in 2005, specializes in genomic tests and services to identify disease causes and enable personalized treatments. Based in Pune, India, the company bridges traditional and genomic-based medicine by offering diagnostic kits like Cervival for cervical cancer screening and tests for genetic risks. They serve healthcare professionals and individuals through accurate, preventive diagnostics, focusing on areas such as pharmacogenomics and hereditary risk assessments.
AyuGen offers Cervivalâ„¢ Kit, Amnisure ROM Test, FSH Polymorphism Test, Cardiovascular Risk Test, and Ayuscreen BRCA Test.
AyuGen operates through Ayugen Biosciences Private Limited.
The legal entities of AyuGen currently have 2 directors, including Manish Sampat Pungliya, Sampat Nensukh Pungliya.